NASDAQ · PGEN
Precigen, Inc.
$6.64+$0.56 (+9.21%)
Precigen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.06% below the high.
Loading market information…
NASDAQ · RGNX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
REGENXBIO Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
REGENXBIO Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$1.30. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow REGENXBIO Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 12, 2025 |
| $0.12-70.73% vs estimate |
| $89.01M-15.51% vs estimate |
| Q4 2024 | Mar 13, 2025 | -$1.01+20.47% vs estimate | $21.21M-10.51% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$1.17-0.86% vs estimate | $24.20M+3.2% vs estimate |
|---|
THE ANALYST VIEW
20 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $19.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.64+$0.56 (+9.21%)
Precigen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.06% below the high.
$25.30+$0.33 (+1.32%)
uniQure N.V.’s quoted price sits in the lower half of its reported 52-week range, 63.85% below the high.
$9.71-$0.05 (-0.46%)
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 36.78% below the high.
$12.78-$0.15 (-1.16%)
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
$6.39-$0.09 (-1.39%)
Solid Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.19% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
$0.74-$0.03 (-4.15%)
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
$3.06-$0.07 (-2.24%)
Lexeo Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 72.16% below the high.
